Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

This study is evaluating a targeted drug called mirvetuximab soravtansine in women whose uterine (endometrial) cancer has come back or kept growing after earlier treatments, focusing specifically on tumors that have a certain protein (folate receptor alpha) on their surface. **You may be eligible if...** - You are a woman with persistent or recurrent endometrial (uterine) cancer confirmed by imaging - Your tumor is a specific type: uterine serous carcinoma, grade 2 or 3 adenocarcinoma, carcinosarcoma, or clear cell carcinoma - Your tumor tests positive for a protein called folate receptor alpha - You have received no more than 3 prior lines of treatment for your recurrent cancer - You are in generally good health (ECOG performance status 0 or 1) - Your heart, liver, and kidney function are adequate **You may NOT be eligible if...** - You have not had measurable disease on imaging - You have received more than 3 prior treatment regimens for recurrent disease - You have previously been treated with folate receptor-targeting drugs - Your side effects from prior treatments have not resolved adequately Talk to your doctor to see if this trial is right for you.